Brean Capital began coverage on shares of Axsome Therapeutics Inc. (NASDAQ:AXSM) in a research note released on Monday morning. The brokerage issued a buy rating and a $20.00 target price on the stock.
Other equities research analysts have also issued research reports about the company. Zacks Investment Research raised Axsome Therapeutics from a sell rating to a hold rating in a research note on Wednesday, July 27th. Cantor Fitzgerald set a $13.00 target price on Axsome Therapeutics and gave the company a buy rating in a research note on Wednesday, August 10th.
Shares of Axsome Therapeutics (NASDAQ:AXSM) opened at 8.33 on Monday. The firm’s 50-day moving average price is $7.53 and its 200 day moving average price is $8.40. The company’s market cap is $159.51 million. Axsome Therapeutics has a 52 week low of $5.37 and a 52 week high of $15.74.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its position in Axsome Therapeutics by 2.0% in the first quarter. JPMorgan Chase & Co. now owns 1,586,656 shares of the company’s stock worth $13,645,000 after buying an additional 31,247 shares during the last quarter. Geode Capital Management LLC acquired a new position in Axsome Therapeutics during the first quarter worth approximately $296,000. Bank of New York Mellon Corp acquired a new position in Axsome Therapeutics during the second quarter worth approximately $161,000. California State Teachers Retirement System acquired a new position in Axsome Therapeutics during the second quarter worth approximately $176,000. Finally, Vanguard Group Inc. raised its position in Axsome Therapeutics by 19.0% in the second quarter. Vanguard Group Inc. now owns 247,937 shares of the company’s stock worth $1,869,000 after buying an additional 39,513 shares during the last quarter. 30.30% of the stock is owned by institutional investors and hedge funds.
About Axsome Therapeutics
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Receive News & Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.